TRAT1 and cancer: This is of particular importance in the context of the potent anti-cancer effects of β-glucan-induced TRIM.30 Indeed, the use of β-glucan preparations in clinical trials for cancer immunotherapies,41,42 often in combination with immune checkpoint inhibitors,42 may require caution given that inflammatory bone loss is a frequent side effect of cancer immunotherapies, particularly of immune checkpoint inhibitors.43,44 Hence, understanding the potential role of β-glucan-induced TRIM in osteoclastogenesis and inflammatory bone loss is imperative.